Neumora Therapeutics Inc (NASDAQ: NMRA)’s stock price has plunge by 4.98relation to previous closing price of 0.91. Nevertheless, the company has seen a -12.04% plunge in its stock price over the last five trading sessions. accessnewswire.com reported 2025-04-02 that NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=140483&wire=1 or contact Joseph E. Levi, Esq.
Is It Worth Investing in Neumora Therapeutics Inc (NASDAQ: NMRA) Right Now?
Additionally, the 36-month beta value for NMRA is 2.89. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for NMRA is 56.00M and currently, short sellers hold a 23.03% ratio of that float. The average trading volume of NMRA on April 02, 2025 was 3.29M shares.
NMRA’s Market Performance
NMRA’s stock has seen a -12.04% decrease for the week, with a -32.00% drop in the past month and a -91.33% fall in the past quarter. The volatility ratio for the week is 8.93%, and the volatility levels for the past 30 days are at 9.18% for Neumora Therapeutics Inc The simple moving average for the past 20 days is -20.54% for NMRA’s stock, with a -88.79% simple moving average for the past 200 days.
Analysts’ Opinion of NMRA
Stifel gave a rating of “Hold” to NMRA, setting the target price at $2 in the report published on March 07th of the current year.
NMRA Trading at -38.26% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.42% of loss for the given period.
Volatility was left at 9.18%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares sank -33.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.11% lower at present.
During the last 5 trading sessions, NMRA fell by -13.27%, which changed the moving average for the period of 200-days by -90.50% in comparison to the 20-day moving average, which settled at $1.2059. In addition, Neumora Therapeutics Inc saw -90.95% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Henry Gosebruch, who proposed sale 15,000 shares at the price of $1.43 back on Mar 12 ’25. After this action, Henry Gosebruch now owns shares of Neumora Therapeutics Inc, valued at $21,450 using the latest closing price.
BERNS PAUL L, the insider of Neumora Therapeutics Inc, sale 13,871 shares at $1.69 during a trade that took place back on Feb 18 ’25, which means that BERNS PAUL L is holding 7,405,004 shares at $23,468 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.92. Equity return is now at value -64.48, with -59.96 for asset returns.
Based on Neumora Therapeutics Inc (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -98.72.
Currently, EBITDA for the company is -263.46 million with net debt to EBITDA at 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.51.
Conclusion
In conclusion, Neumora Therapeutics Inc (NMRA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
